GLB prevents tumor metastasis of Lewis lung carcinoma by inhibiting tumor adhesion actions.
OBJECTIVE
To investigate the inhibitory effect of a new compound of GLB on tumor metastasis in vivo and analyze its actions on tumor cell adhesion to clarify its mechanism.


METHODS
The effect of GLB on tumor metastasis was analyzed by Lewis lung carcinoma model. The pathological morphology of lung alveolar was evaluated by hematoxylin-eosin staining. The effect of GLB on the proliferation of human prostate cancer cell (PC-3M, with a high metastatic characteristic) was studied using the MTT method, and its actions on PC-3M cell adhesion to human umbilical vein endothelial cells (HUVEC) and laminin were analyzed in vitro.


RESULTS
GLB (100 mg/kg/d for 28 d, ig) reduced the number of lung colonies of Lewis lung carcinoma metastasis significantly (P<0.05). Simultaneously, GLB could mitigate the damage of lung alveolar caused by metastasic tumor deposits. In vitro, GLB inhibited dramatically the adhesion of PC-3M cells to HUVEC (P< 0.01) and laminin (P<0.05), without cytotoxic or anti-proliferative action on PC-3M cells.


CONCLUSIONS
GLB has anti-tumor metastatic activity, which partly depends on its inhibition of tumor adhesion.
Pan
Yan
Y
Department of Pharmacology, School of Basic Medical Sciences and State Key Laboratory of Natural Biomimetic Drugs, Peking University, Beijing 100083, China.
Song
Qian-Liu
QL
Lin
Yan-Hua
YH
Lu
Ning
N
Yu
He-Ming
HM
Li
Xue-Jun
XJ
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D018827:Carcinoma, Lewis Lung / Q000473:pathology*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D042783:Endothelial Cells / Q000502:physiology; D005260:Female; D006801:Humans; D007797:Laminin / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D015394:Molecular Structure; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D010069:Oxadiazoles / Q000737:chemistry / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000503:physiopathology; D011714:Pyrans / Q000737:chemistry / Q000494:pharmacology*; D013141:Spiro Compounds / Q000737:chemistry / Q000494:pharmacology*; D014471:Umbilical Veins / Q000166:cytology
C512376:(2''S,3aR,6S,7aR)-3''-acetyl-3a,7a-dihydro-2,2,2'-2',-tetramethyl-5'-(4-bromophenyl)-spiro(spiro(1,3-dioxolo(4,5-D)-pyrane-6(7H),5'(4'H)-1',3'-dioxolo)-7(6H),2''(3''H)-(1,3,4)-oxadiazole); D000970:Antineoplastic Agents; D007797:Laminin; D010069:Oxadiazoles; D011714:Pyrans; D013141:Spiro Compounds